This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Bin, X. X.
Right arrow Articles by Malinverni, R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bin, X. X.
Right arrow Articles by Malinverni, R.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, June 2000, p. 1761-1764, Vol. 44, No. 6
0066-4804/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.

Effect of Azithromycin plus Rifampin versus Amoxicillin Alone on Eradication and Inflammation in the Chronic Course of Chlamydia pneumoniae Pneumonitis in Mice

Xie Xiao Bin,1,dagger Katerina Wolf,1,Dagger Thomas Schaffner,2 and Raffaele Malinverni1,3,*

Department of Clinical Research,1 Institute for Pathology,2 and Medical Policlinic,3 Inselspital, University of Bern, Bern, Switzerland

Received 2 July 1999/Returned for modification 22 December 1999/Accepted 21 March 2000

The effects of treatment with azithromycin plus rifampin (A+R), amoxicillin (A), or placebo (P) on the chronic course of experimental Chlamydia pneumoniae pneumonitis in mice were assessed by culture, PCR, and immunocytochemistry as well as by degree of inflammation in lung tissue. Eradication of the pathogen was significantly more frequent and inflammation in tissue was significantly reduced after treatment with A+R compared to after treatment with A or P. Combination therapy with azithromycin plus rifampin showed favorable effects in the chronic course of C. pneumoniae pneumonitis.

* Corresponding author. Mailing address: Department of Medicine, Hôpital des Cadolles, 2000 Neuchâtel, Switzerland. Phone: 032 722 91 27. Fax: 032 722 96 58. E-mail: Raffaele.Malinverni{at}ne.ch.

dagger Present address: Abteilung für Pneumologie, Departement Innere Medizin, Universitätsspital, CH-8091 Zürich, Switzerland.

Dagger Present address: NIH/NIAID Rocky Mountain Labs, Hamilton, MT 59840.

Antimicrobial Agents and Chemotherapy, June 2000, p. 1761-1764, Vol. 44, No. 6
0066-4804/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.


This article has been cited by other articles:

  • Rios, A. M., Fonseca-Aten, M., Mejias, A., Chavez-Bueno, S., Katz, K., Gomez, A. M., McCracken, G. H. Jr., Ramilo, O., Hardy, R. D. (2005). Microbiologic and Immunologic Evaluation of a Single High Dose of Azithromycin for Treatment of Experimental Mycoplasma pneumoniae Pneumonia. Antimicrob. Agents Chemother. 49: 3970-3973 [Abstract] [Full Text]  
  • de Kruif, M. D., van Gorp, E. C.M., Keller, T. T., Ossewaarde, J. M., ten Cate, H. (2005). Chlamydia pneumoniae infections in mouse models: relevance for atherosclerosis research. Cardiovasc Res 65: 317-327 [Abstract] [Full Text]  
  • Tormakangas, L., Alakarppa, H., David, D. B., Leinonen, M., Saikku, P. (2004). Telithromycin Treatment of Chronic Chlamydia pneumoniae Infection in C57BL/6J mice. Antimicrob. Agents Chemother. 48: 3655-3661 [Abstract] [Full Text]  
  • Tormakangas, L., Saario, E., Bem David, D., Bryskier, A., Leinonen, M., Saikku, P. (2004). Treatment of acute Chlamydia pneumoniae infection with telithromycin in C57BL/6J mice. J Antimicrob Chemother 53: 1101-1104 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»